Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3438-3446

  Avci, Berrin ^a   Avci, Remzi ^a   Inan, Ümit Übeyt ^b   Kaderli, Berkant ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CASPASE 3; CASPASE 9; DNA FRAGMENT; EOSIN; HEMATOXYLIN; PARAFFIN; PEGAPTANIB; SODIUM CHLORIDE; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; EMBEDDING; ENUCLEATION; EYE TOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PHOTORECEPTOR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; TIME; TREATMENT DURATION; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYMOLOGY; INJECTION; METABOLISM; PATHOLOGY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; APTAMERS, NUCLEOTIDE; CASPASE 3; CASPASE 9; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INJECTIONS; MALE; PHOTORECEPTOR CELLS, VERTEBRATE; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67649973996     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2871     Document Type: Article

References (45)

1. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Kepmen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563.
3. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3974-3979.
4. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246: 1306-1309.
5. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of Bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823.
6. Ameri H, Chader GJ, Kim JG, et al. The effects of intravitreous bevacizumab on retinal neovascular membrane and capillaries in rabbits. Invest Ophthalmol Vis Sci. 2007;48:5708-5714.
7. Dib E, Maria M, Longo-Maugeri IM, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci. 2008;49:1097-1100.
8. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
9. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
10. Klettner AK, Roider J. Comparison of bevacizumab, ranibizumab and pegaptanib in vitro efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-4527.
11. Kaempf S, Johnen S, Salz AK, et al. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci. 2008;49:3164-3170.
12. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245:1837-1842.
13. Inan UU, Avci B, Kusbeci T, et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48:1773-1781.
14. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007;143:995-1002.
15. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351:2805-2816.
16. Ng EWM, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-132.
17. Gryziewics L. Regulatory aspects of drug approval for macular degeneration. Adv Drug Deliv Rev. 2005;57:2092-2098.
18. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2006;28:36-44.
19. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
20. Bhatnagar P, Spanide RF, Takahashi BS, et al. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2007;27:846-850.
21. Foy JW, Rittenhouse K, Modi M, Patel M. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J Ocul Pharmacol Ther. 2007;23:452-466.
22. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
23. Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003; 199:221-228.
24. Lambooij AC, Kliffen M, Kuijpers RWAM, et al. Apoptosis is present in the primate macula at all ages. Graefes Arch Clin Exp Ophthalmol. 2000;238:508-514.
25. Meresman GF, Bilotas MA, Lombardi E, et al. Effect of GnRH analogues on apoptosis and release of interleukin-1 β and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod. 2003;18:1767-1771.
26. Kasahar Y, Tuder RM, Taraseviciene-Steward L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-1319.
27. Ding XM, Mao BY, Jiang S, et al. Neuroprotective effect of exogenous vascular endothelial growth factor on rat spinal cord neurons in vitro hypoxia. Chin Med J (Engl). 2005;118:1644-1650.
28. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effects in vitro ischemia. Proc Natl Acad Sci USA. 2000;97:10242-10247.
29. Böcker-Meffert S, Rosenstiel P, Röhl C, et al. Erythropoietin and VEGF promote neural outgrowth from retinal explant in postnatal rats. Invest Ophthalmol Vis Sci. 2002;43:2021-2026.
30. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci. 2000;12:4243-4254.
31. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci. 2006;47:3135-3142.
32. Liljekvist-Soltic I, Olofsson J, Johansson K. Progenitor cell-derived factors enhance photoreceptor survival in rat retinal explants. Brain Res. 2008;1227:226-233.
33. Nishijima K, Ng Y-S, Zhong L, Bradley J, et al. VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
34. Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for survival role on Müller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
35. Linsenmeier RA. Electrophysiological consequences of retinal hypoxia. Graefes Arch Clin Exp Ophthalmol. 1990;228:143-150.
36. Gora-Kupilas K, Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 2005;43: 31-39.
37. Luthra S, Narayanan R, Marques LEA, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26:512-518.
38. Kim JH, Kim C, Kim JH, et al. Absence of intravitreal bevacizumabinduced neuronal toxicity in the retina. Neurotoxicology. 2008; 29:1131-1135.
39. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;29;:841-844.
40. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288:371-378.
41. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625-6631.
42. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol. 2009;247(2):171-177.
43. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008; 49:522-527.
44. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
45. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007; 91:1230-1233.